Continuous positive airway pressure effect on visual acuity in patients with type 2 diabetes and obstructive sleep apnoea: a multicentre randomised controlled trial
West SD., Prudon B., Hughes J., Gupta R., Mohammed SB., Gerry S., Stradling JR.
<jats:p>We sought to establish whether continuous positive airway pressure (CPAP) for obstructive sleep apnoea (OSA) in people with type 2 diabetes and diabetic macular oedema (DMO) improved visual acuity.</jats:p><jats:p>We randomly assigned 131 eligible patients aged 30–85 years from 23 UK centres with significant DMO causing visual impairment (LogMAR letters identified ≥39 and ≤78, score 0.92–0.14) plus severe OSA on screening to either usual ophthalmology care (n=67) or usual ophthalmology care plus CPAP (n=64) for 12 months.</jats:p><jats:p>Mean age of participants was 64 years, 73% male, mean body mass index 35.0 kg·m<jats:sup>−</jats:sup><jats:sup>2</jats:sup>. Mean 4% oxygen desaturation index was 36 events·h<jats:sup>−1</jats:sup>. There was no significant difference in the visual acuity at 12 months between the CPAP group and the control group (mean LogMAR 0.33 (95% CI 0.29–0.37) <jats:italic>versus</jats:italic> 0.31 (95% CI 0.27–0.35); p=0.39), and no significant correlation between change in LogMAR and average CPAP use. The median±<jats:sc>sd</jats:sc> (range) daily CPAP use was 3.33±2.25 (0–7.93) h at 3 months, 3.19±2.54 (0–8.07) h at 6 months and 3.21±2.70 (0–7.98) h at 12 months.</jats:p><jats:p>CPAP therapy for OSA did not improve visual acuity in people with type 2 diabetes and DMO compared with usual care alone over 12 months.</jats:p>